EGFR and non-small cell lung carcinoma: Notably, PC9/ER cells pretreated with UNC0638 (100 nM) displayed enhanced sensitivity to Erlotinib compared to non-pretreated cells, suggesting that the inhibitor has value as a treatment for EGFR-TKI-resistant NSCLC (Fig. 2b).